Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...
Clinical advantage observed in refractory atopic dermatitis with lebrikizumab plus topical corticosteroids where ciclosporin ...
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
For adults with atopic dermatitis, rocatinlimab treatment yields significant improvements across clinical end points.
6don MSN
Kymera Therapeutics stock soars 46%. Why investors are excited about its anti-inflammatory drug.
Researchers are probing its efficacy in patients with Type 2 inflammatory diseases, which are triggered by an overactive ...
Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.
Zacks Investment Research on MSN
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...
Children saw improvements in their atopic dermatitis with tapinarof regardless of their atopic comorbidities, according to ...
SAN FRANCISCO, Nov. 19, 2025 /PRNewswire/ -- ixlayer, the leading cloud-based platform powering end-to-end direct-to-patient (DTP) healthcare, today announced the launch of SkinLink.us--a platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback